A Margin-negative R0 Resection Accomplished with Minimal Postoperative Complications is the Surgeon's Contribution to Long-term Survival in Pancreatic Cancer

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2006 Dec 19

PMID 17175452

Citations 116

Authors

Thomas J Howard

Joseph E Krug

Jian Yu

Nick J Zyromski

C Max Schmidt

Lewis E Jacobson

James A Madura

Eric A Wiebke

Keith D Lillemoe

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer has a poor prognosis with complete surgical resection being the only therapy to offer a realistic chance for long-term survival. The aim of this study is to identify surgery-related variables that influence long-term survival. Between 1990 and 2002, 226 consecutive patients (mean age of 64+/-11 years) had resection for pancreatic adenocarcinoma. Prognostic variables in these patients were analyzed using univariate and multivariate analysis. Two hundred four patients (90%) had pancreaticoduodenectomy, 13 patients (6%) had distal pancreatectomy, and 9 patients (4%) had a TP. Stage I disease was present in 50 (22%), stage II disease in 170 (75%), and stage III disease in 6 (3%). R0 resections were achieved in 70%. Operative morbidity was 36% and 30-day mortality was 6%. Actual 1-year, 3-year, and 5-year survival rates were 49% (n=111), 14% (n=31), and 4% (n=9). Using multivariate analysis: tumor size, tumor differentiation, obtaining an R0 resection, and lack of postoperative complications were variables associated with long-term survival. Long-term survival in patients with pancreatic cancer after resection remains poor. Achieving a margin negative resection (R0) with no postoperative complications are prognostic variables that can be affected by the surgeon.

Citing Articles

Digestive cancers: mechanisms, therapeutics and management.

Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M Signal Transduct Target Ther. 2025; 10(1):24.

PMID: 39809756 PMC: 11733248. DOI: 10.1038/s41392-024-02097-4.

Clinicopathological predictive factors in long-term survivors who underwent surgery for pancreatic ductal adenocarcinoma: A single-center propensity score matched analysis.

Ingaldi C, DAmbra V, Ricci C, Alberici L, Minghetti M, Grego D World J Surg. 2024; 48(12):3001-3013.

PMID: 39542862 PMC: 11619735. DOI: 10.1002/wjs.12397.

Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies.

Esfahani S, Ma H, Krishna S, Shuvaev S, Sabbagh M, Deffler C Theranostics. 2024; 14(15):5745-5761.

PMID: 39346545 PMC: 11426233. DOI: 10.7150/thno.100116.

Safety and learning curve analysis of robotic-assisted pancreaticoduodenectomy: experience of a single surgeon.

Yu Y, Changyong E, Lin C, Wang L, Jiang T J Robot Surg. 2024; 18(1):92.

PMID: 38400999 DOI: 10.1007/s11701-024-01844-7.

Postoperative complications and prognosis based on type of surgery in ulcerative colitis patients with colorectal cancer: A multicenter observational study of data from the Japanese Society for Cancer of the Colon and Rectum.

Hoshino N, Hida K, Yoshida S, Ueno K, Noguchi T, Ishihara S Ann Gastroenterol Surg. 2023; 7(4):626-636.

PMID: 37416741 PMC: 10319604. DOI: 10.1002/ags3.12659.

References

BAUMEL H, Huguier M, Manderscheid J, Fabre J, Houry S, Fagot H . Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg. 1994; 81(1):102-7. DOI: 10.1002/bjs.1800810138. View

Gudjonsson B . Survival statistics gone awry: pancreatic cancer, a case in point. J Clin Gastroenterol. 2002; 35(2):180-4. DOI: 10.1097/00004836-200208000-00011. View

Lockhart A, Rothenberg M, Berlin J . Treatment for pancreatic cancer: current therapy and continued progress. Gastroenterology. 2005; 128(6):1642-54. DOI: 10.1053/j.gastro.2005.03.039. View

Pedrazzoli S, Dicarlo V, Dionigi R, Mosca F, Pederzoli P, Pasquali C . Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg. 1998; 228(4):508-17. PMC: 1191525. DOI: 10.1097/00000658-199810000-00007. View

Mao C, Domenico D, Kim K, Hanson D, Howard J . Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995; 130(2):125-34. DOI: 10.1001/archsurg.1995.01430020015001. View

Tseng J, Raut C, Lee J, Pisters P, Vauthey J, Abdalla E . Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004; 8(8):935-49. DOI: 10.1016/j.gassur.2004.09.046. View

Jemal A, Murray T, Ward E, Samuels A, Tiwari R, Ghafoor A . Cancer statistics, 2005. CA Cancer J Clin. 2005; 55(1):10-30. DOI: 10.3322/canjclin.55.1.10. View

Howard T, Villanustre N, Moore S, DeWitt J, LeBlanc J, Maglinte D . Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head. J Gastrointest Surg. 2003; 7(8):1089-95. DOI: 10.1016/j.gassur.2003.07.010. View

Warshaw A, Thayer S . Pancreaticoduodenectomy. J Gastrointest Surg. 2004; 8(6):733-41. PMC: 3811050. DOI: 10.1016/j.gassur.2004.03.005. View

10.

Gudjonsson B . Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg. 1995; 181(6):483-503. View

11.

Lim J, Chien M, Earle C . Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2002; 237(1):74-85. PMC: 1513971. DOI: 10.1097/00000658-200301000-00011. View

12.

Pedrazzoli S, Beger H, Obertop H, Andren-Sandberg A, Fernandez-Cruz L, Henne-Bruns D . A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg. 1999; 16(4):337-45. DOI: 10.1159/000018744. View

13.

Schafer M, Mullhaupt B, Clavien P . Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg. 2002; 236(2):137-48. PMC: 1422559. DOI: 10.1097/00000658-200208000-00001. View

14.

Manu M, Buckels J, Bramhall S . Molecular technology and pancreatic cancer. Br J Surg. 2000; 87(7):840-53. DOI: 10.1046/j.1365-2168.2000.01510.x. View

15.

Wagner M, Redaelli C, Lietz M, Seiler C, Friess H, Buchler M . Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004; 91(5):586-94. DOI: 10.1002/bjs.4484. View

16.

Picozzi V, Kozarek R, Traverso L . Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg. 2003; 185(5):476-80. DOI: 10.1016/s0002-9610(03)00051-5. View

17.

Yi S, Miwa K, Ohta T, Kayahara M, Kitagawa H, Tanaka A . Innervation of the pancreas from the perspective of perineural invasion of pancreatic cancer. Pancreas. 2003; 27(3):225-9. DOI: 10.1097/00006676-200310000-00005. View

18.

Sperti C, Pasquali C, Piccoli A, Pedrazzoli S . Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg. 1996; 83(5):625-31. DOI: 10.1002/bjs.1800830512. View

19.

Farnell M, Pearson R, Sarr M, DiMagno E, Burgart L, Dahl T . A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005; 138(4):618-28. DOI: 10.1016/j.surg.2005.06.044. View

20.

Sohn T, Yeo C, Cameron J, Koniaris L, Kaushal S, Abrams R . Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2001; 4(6):567-79. DOI: 10.1016/s1091-255x(00)80105-5. View